Early- and Delayed Antipsychotic Response and Prediction of Outcome in 528 Severely Impaired Patients with Schizophrenia Treated with Amisulpride

Abstract

Introduction: ‘Early-onset’ studies have shown that symptomatic response often occurs early and that early symptomatic response is predictive for later outcome. Limiting factors of these studies include the restriction on symptomatic outcome, the inclusion of mostly moderately ill patients, and the use of various antipsychotics.

Methods: Response and remission rates were assessed in 528 severely ill patients with schizophrenia at baseline, week 2, 4 and 12 using PANSS, SWN-K, CGI-S, and SOFAS. The clinical measures were combined to one outcome criterion (CombOut). Predicitive validity was analyzed for CombOut using linear regression models.

Results: Rate and time to response differed markedly between outcome measures. 32% reached positive symptom response at week 2, 58% at week 4 and 85% at week 12. Non-response at week 4, but not at week 2 was predictive for later non-response. The combined outcome criterion was best predicted by early response in subjective wellbeing (T=−7.88, p<0.001) and social functioning (T=−7.43, p<0.001).

Discussion: Rate and time to response might depend on sample characteristics and outcome measure. In severely ill patients early antipsychotic response is possibly delayed from the first 2 to the first 4 weeks. Early response in subjective wellbeing and social functioning are strong predictors for overall outcome, which make them a useful supplementation to the assessment of symptomatic response.

References

• 1 Leucht S, Busch R, Kissling W. Early prediction of antipsychotic nonresponse among patients with schizophrenia.  The Journal of clinical psychiatry. 2007;  68 352-360
• 2 Lambert M, Schimmelmann BG, Naber D. et al . Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia.  The Journal of clinical psychiatry. 2006;  67 1690-1697
• 3 Lambert M, Naber D, Eich FX. et al . Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride.  Acta psychiatrica Scandinavica. 2007;  115 106-113
• 4 Lehman AF, Lieberman JA, Dixon LB. et al . Practice guideline for the treatment of patients with schizophrenia, second edition.  The American journal of psychiatry. 2004;  161 1-56
• 5 Agid O, Kapur S, Arenovich T. et al . Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected.  Archives of general psychiatry. 2003;  60 1228-1235
• 6 Correll CU, Malhotra AK, Kaushik S. et al . Early prediction of antipsychotic response in schizophrenia.  The American journal of psychiatry. 2003;  160 2063-2065
• 7 Chang YC, Lane HY, Yang KH. et al . Optimizing early prediction for antipsychotic response in schizophrenia.  Journal of clinical psychopharmacology. 2006;  26 554-559
• 8 Leucht S, Busch R, Hamann J. et al . Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended.  Biological psychiatry. 2005;  57 1543-1549
• 9 Li M, Fletcher PJ, Kapur S. Time course of the antipsychotic effect and the underlying behavioral mechanisms.  Neuropsychopharmacology. 2007;  32 263-272
• 10 Agid O, Seeman P, Kapur S. The “delayed onset” of antipsychotic action–an idea whose time has come and gone.  J Psychiatry Neurosci. 2006;  31 93-100
• 11 Flyckt L, Mattsson M, Edman G. et al . Predicting 5-year outcome in first-episode psychosis: construction of a prognostic rating scale.  The Journal of clinical psychiatry. 2006;  67 916-924
• 12 Hofer A, Rettenbacher MA, Edlinger M. et al . Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine.  Pharmacopsychiatry. 2007;  40 1-8
• 13 Andreasen NC, Carpenter  Jr  WT, Kane JM. et al . Remission in schizophrenia: proposed criteria and rationale for consensus.  Am J Psychiatry. 2005;  162 441-449
• 14 Lambert M, Schimmelmann BG, Karow A. et al . Subjective well-being and initial dysphoric reaction under antipsychotic drugs – concepts, measurement and clinical relevance.  Pharmacopsychiatry. 2003;  36 (Suppl 3) S181-S190
• 15 DeHaan L, Weisfelt M, Dingemans PM. et al . Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale [Medico-economic study of Leponex (clozapine) in the Bordeaux Charles Perrens Hospital Center].  Psychopharmacology (Berl). 2002;  162 24-28
• 16 Schimmelmann BG, Paulus S, Schacht M. et al . Subjective distress related to side effects and subjective well-being in first admitted adolescents with early-onset psychosis treated with atypical antipsychotics.  J Child Adolesc Psychopharmacol. 2005;  15 249-258
• 17 Putzhammer A, Perfahl M, Pfeiff L. et al . Correlation of subjective well-being in schizophrenic patients with gait parameters, expert-rated motor disturbances, and psychopathological status.  Pharmacopsychiatry. 2005;  38 132-138
• 18 Karow A, Czekalla J, Dittmann RW. et al . Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia.  The Journal of clinical psychiatry. 2007;  68 75-80
• 19 Wehmeier PM, Kluge M, Schacht A. et al . Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia.  Schizophrenia research. 2007;  91 178-186
• 20 Wehmeier PM, Kluge M, Schneider E. et al . Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia.  Progress in neuro-psychopharmacology & biological psychiatry. 2007;  31 703-712
• 21 WHO .The ICD-10 classification of mental and behavioural disorders. Diagnostic criteria for research. In. Geneva: WHO 1993
• 22 Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia.  SchizophrBull. 1987;  13 261-276
• 23 Guy W. Clinical Global Impression. In: Guy W, ed ECDEU Assessment Manual for Psychopharmacology, rev. Rockville. US Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch. Division of Extramural Research Programms 1976: pp. 218-222
• 24 APA .Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington. DC: American Psychiatric Press 1994
• 25 Naber D, Moritz S, Lambert M. et al . Improvement of schizophrenic patients; subjective well-being under atypical antipsychotic drugs.  Schizophr Res. 2001;  50 ((1–2)) 79-88
• 26 Haro JM, Kamath SA, Ochoa S. et al . The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia.  Acta Psychiatr Scand Suppl. 2003;  16-23
• 27 Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables.  Int Clin Psychopharmacol. 1995;  10 (Suppl 3) 133-138
• 28 Lambert M, Conus P, Schimmelmann BG. et al . Comparison of olanzapine and risperidone in 367 first-episode patients with non-affective or affective psychosis: results of an open retrospective medical record study.  Pharmacopsychiatry. 2005;  38 206-213
• 29 Haro JM, Edgell ET, Novick D. et al . Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study.  Acta Psychiatr Scand. 2005;  111 220-231
• 30 Kopelowicz A, Liberman RP. Biobehavioral treatment and rehabilitation of schizophrenia.  Harv Rev Psychiatry. 1995;  3 55-64
• 31 Haro JM, Novick D, Suarez D. et al . Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study.  Journal of clinical psychopharmacology. 2006;  26 571-578
• 32 Liberman RP, Kopelowicz A. Recovery from schizophrenia: a concept in search of research. Psychiatric services. Washington, DC 2005 56: 735-742
• 33 Aiken LR. Formulas for equating ratings on different scales.  Educational and Psychological Measurement. 1987;  51-54
• 34 Perkins DO, Gu H, Boteva K. et al . Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis.  Am J Psychiatry. 2005;  162 1785-1804
• 35 Crespo-Facorro B, Pelayo-Teran JM, Perez-Iglesias R. et al . Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.  Journal of psychiatric research. 2007;  41 659-666
• 36 McDermott BE, Sautter FJ, Garver DL. Heterogeneity of schizophrenia: relationship to latency of neuroleptic response.  Psychiatry research. 1991;  37 97-103
• 37 Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics.  Arch Gen Psychiatry. 2003;  60 553-564
• 38 Semiz UB, Cetin M, Basoglu C. et al . Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia.  Progress in neuro-psychopharmacology & biological psychiatry. 2007;  31 1330-1336
• 39 Remington G, Saha A, Chong SA. et al . Augmentation strategies in clozapine-resistant schizophrenia.  CNS drugs. 2005;  19 843-872
• 40 de Haan L, Nimwegen L, Amelsvoort T. et al . Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia.  Pharmacopsychiatry. 2008;  41 125-128
• 41 Jager M, Messer T, Laux G. et al . Standardized remission criteria in schizophrenia: descriptive validity and comparability with previously used outcome measures.  Pharmacopsychiatry. 2008;  41 190-195
• 42 Wiersma D, Wanderling J, Dragomirecka E. et al . Social disability in schizophrenia: its development and prediction over 15 years in incidence cohorts in six European centers.  Psychological medicine. 2000;  30 1155-1167

Correspondence